ESR1 and ductal breast carcinoma in situ: Immunoblot assays in the different engineered cell lines verified ER/PR expression levels that were similar to endogenous receptors in T47D breast cancer cells and lack of receptors in parental and vector control DCIS.COM cells (Fig. 2a).